Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is…

Biotechnology

US, Charlottesville [HQ]

Summary
IR
Fin. Reports
Financials
Leadership & Strategy
Possible Catalysts

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Adial Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

Adial Pharmaceuticals, Inc. can't present any analysts estimates at the moment detail analysis.